Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2026)

Royalty Pharma has reported Other Non-Current Assets for 8 years, with the latest figure at $76.8 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 109.36% year-over-year to $76.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.8 million (up 109.36% YoY) and the FY2025 annual result came in at $79.3 million, up 136.46% from the prior year.
• Other Non-Current Assets fell to $76.8 million in Q1 2026 per RPRX's latest filing, from $79.3 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $86.6 million in Q3 2025 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $38.5 million and a median of $30.6 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets slumped 83.99% in 2024, then jumped 717.89% in 2025.
• Over 5 years, Other Non-Current Assets stood at $29.6 million in 2022, then slumped by 77.99% to $6.5 million in 2023, then soared by 414.17% to $33.5 million in 2024, then surged by 136.46% to $79.3 million in 2025, then decreased by 3.08% to $76.8 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $76.8 million, $79.3 million, and $86.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.